Megan Brooks In recent years, media reports touting ketamine as a fast-acting, highly effective treatment for severe depression have increased. In part, this phenomenon is due to the US Food and Drug Administration’s (FDA’s) 2019 approval of ketamine’s cousin, esketamine (Spravato), the first antidepressant in a new drug class for treatment-resistant depression (TRD). Yet, news...
Tag: <span>esketamine</span>
Post
Promising new drug for treatment-resistant depression – esketamine
Treatment-resistant depression affects 1 in 3 of the estimated 16.2 million adults in the U.S. who have suffered at least one major depressive episode. For them, two or more therapies have failed and the risk of suicide is much greater. It’s a grim prognosis. The chemical structure of esketamine. The chemical structure of ketamine. As there...